Truist analyst Richard Newitter lowered the firm’s price target on Inari Medical to $65 from $75 and keeps a Hold rating on the shares as part of a broader research note previewing Q4 earnings in MedTech. The company offered positive guidance for FY23 revenue growth but the stock did not rebound amid mounting competition fears and concerns around sustainability of above 20% core VTE trajectory, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NARI:
- Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Penumbra price target raised to $270 from $240 at BTIG
- Inari Medical director sells $3.68M in common stock
- Inari:1st patient enrolled in ‘clinical outcomes’ study of ClotTriever for DVT
- Inari Medical sees FY23 revenue $470M-$480M, consensus $450.75M
